CDSCO Classification of Medical Devices (2026 Update)

CDSCO Classification of Medical Devices (2026 Update)

India’s medical device regulatory framework continues to evolve, and the 2026 update to device classification brings important clarifications for manufacturers, importers, and distributors. The Central Drugs Standard Control Organization (CDSCO), operating under the Ministry of Health and Family Welfare, is responsible for regulating medical devices in India. With growing innovation in digital health, AI-based tools, and implantable technologies, correct classification has become more critical than ever.

Regulatory Background

Medical devices in India are regulated under the Drugs and Cosmetics Act and the Medical Devices Rules (MDR 2017). The Medical Devices Rules introduced a risk-based classification system, aligning India with global regulatory practices followed in the EU and other jurisdictions. The 2026 update further refines classification guidelines, especially for software-driven devices and emerging technologies.

Read More What is CDSCO Medical Device Import Certificate?

What Is Medical Device Classification?

Classification determines the level of regulatory control applied to a device. The higher the risk associated with the device, the stricter the regulatory requirements.

Under CDSCO, medical devices are categorized into four classes:

• Class A – Low Risk
• Class B – Low to Moderate Risk
• Class C – Moderate to High Risk
• Class D – High Risk

The classification is based on factors such as the following:

• Degree of invasiveness
• Duration of body contact
• Whether the device is implantable
• Whether it sustains or supports life
• Potential risk to patients

Overview of Device Classes

Class A (Low Risk)

These devices pose minimal potential harm to users.

Examples:

• Surgical dressings
• Thermometers (non-invasive)
• Basic hospital furniture

Regulatory Control:

• Registration with State Licensing Authority (SLA)
• Self-certification in many cases
• Lower government fees

Class A manufacturers are subject to basic quality management requirements but face relatively simplified approvals.

Class B (Low–Moderate Risk)

These devices carry slightly higher risk and require closer oversight.

Examples:

• Hypodermic needles
• Suction equipment
• Blood pressure monitors

Regulatory Control:

• License from State Licensing Authority
• Quality Management System (QMS) compliance
• Audit by notified bodies

Class B devices require more documentation and inspection compared to Class A.

Class C (Moderate–High Risk)

These devices may have a significant impact on patient health.

Examples:

• Ventilators
• Orthopedic implants
• Infusion pumps

Regulatory Control:

• Approval from Central Licensing Authority (CLA)
• Detailed technical documentation
• Clinical evaluation data
• Periodic inspections

Class D (High Risk)

These are life-supporting or life-sustaining devices with the highest level of regulatory scrutiny.

Examples:

• Heart valves
• Implantable defibrillators
• Coronary stents

Regulatory Control:

• Approval strictly through Central Licensing Authority
• Clinical investigation requirements
• Intensive review of safety and performance data
• Post-market surveillance obligations

2026 Key Updates in Classification

The 2026 update focuses on modern healthcare technologies and clarity in classification rules.

1. Expanded Coverage of Software and AI-Based Devices

Software as a Medical Device (SaMD) has received greater regulatory clarity. AI-driven diagnostic tools, health monitoring apps with clinical claims, and machine learning imaging software are now clearly categorized under risk-based rules depending on the following:

• Intended use
• Clinical decision support function
• Impact of incorrect output

This update ensures that digital health products are not left in regulatory gray areas.

2. Revised Risk Interpretation Guidelines

CDSCO has refined interpretation notes in the First Schedule of MDR 2017. These clarifications help manufacturers better determine whether their device falls under invasive, non-invasive, active, or special rules categories.

Misclassification can lead to penalties, so these clarifications reduce compliance uncertainty.

3. Greater Emphasis on Intended Use

The 2026 revision strongly reinforces that intended use determines classification. Marketing claims, labeling, instructions for use, and promotional materials must align with the chosen risk category.

Even minor wording changes can shift a device from Class B to Class C if it suggests diagnostic or life-supporting functionality.

4. Strengthened Post-Market Surveillance

Higher-class devices now face stricter vigilance reporting timelines. Manufacturers must maintain:

• Adverse event reporting systems
• Periodic safety update reports (PSUR)
• Recall procedures

Read More CDSCO Certificate Registration in Delhi: Documents, Process, and Fees

Licensing Authorities: SLA vs CLA

The licensing authority depends on the device class:

• Class A & B: Regulated primarily by State Licensing Authority
• Class C & D: Regulated by Central Licensing Authority under CDSCO

This distinction affects documentation, approval timelines, and regulatory interactions.

Import and Manufacturing Requirements

For manufacturers:

• A manufacturing license is mandatory before commercial production
• QMS compliance aligned with ISO 13485 principles is expected

For importers:

• Import License from CDSCO
• Free Sale Certificate from country of origin
• Technical documentation and device master file

Why Correct Classification Matters

Incorrect classification can result in:

• License rejection
• Regulatory penalties
• Product seizure
• Market withdrawal
• Legal action

Over-classification may increase compliance costs unnecessarily, while under-classification can expose businesses to serious regulatory risks. A proper regulatory strategy involves technical review, regulatory consultation, and careful evaluation of intended use statements.

Compliance Strategy for 2026

To ensure smooth approval under updated rules:

1. Conduct a classification assessment using MDR 2017 First Schedule.
2. Review labeling and marketing claims carefully.
3. Prepare complete technical documentation.
4. Ensure QMS implementation before applying.
5. Monitor CDSCO notifications regularly.

For AI and digital device manufacturers, early regulatory consultation is strongly recommended due to evolving interpretations.

Conclusion

The CDSCO Classification of Medical Devices (2026 Update) represents India’s continued move toward a robust, globally aligned regulatory system. By refining risk categorization, expanding software oversight, and strengthening post-market monitoring, CDSCO aims to improve patient safety while supporting innovation.